Lacosamide Patent Expiration
Lacosamide is Used for treating partial-onset seizures in patients with epilepsy aged 17 years and older, either as adjunctive therapy or when oral treatment is temporarily not feasible. It was first introduced by Ucb Inc
Lacosamide Patents
Given below is the list of patents protecting Lacosamide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Motpoly Xr | US11337943 | Lacosamide pharmaceutical composition and dosage form thereof | Jun 05, 2040 | Aucta |
| Motpoly Xr | US11883374 | Lacosamide pharmaceutical composition and dosage form thereof | Jun 05, 2040 | Aucta |
| Motpoly Xr | US12042474 | Lacosamide pharmaceutical composition and dosage form thereof | Jun 05, 2040 | Aucta |
| Vimpat | USRE38551 | Anticonvulsant enantiomeric amino acid derivatives |
Mar 17, 2022
(Expired) | Ucb Inc |
| Vimpat | US5654301 | Amino acid derivative anticonvulsant |
Aug 05, 2014
(Expired) | Ucb Inc |
Lacosamide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Lacosamide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial) | University of Southern Denmark | NA |
RECRUITING
(May 1, 2026)
| PHASE3 |
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis | Indiana University | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE1 |
| Add on Lacosamide Versus High Dose Monotherapy | Brigham and Women's Hospital | NA |
COMPLETED
(Mar 1, 2026)
| PHASE3 |